Navigation Links
Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
Date:10/30/2012

MONTREAL, Oct. 30, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has decided to reschedule its webcast and conference call to discuss financial results for the 2012 third quarter, which was previously scheduled for Wednesday, October 31, 2012 at 8 a.m. ET, due to the severe weather conditions and power outages associated with Hurricane Sandy. The webcast and conference call has been rescheduled for November 2, 2012 at 8 a.m. ET and the financial results will be issued at 6:00 a.m. ET.

The dial-in number to participate on this call is (877) 281-0402, confirmation code 39252322.  International callers should dial (631) 813-4869, confirmation code 39252322. A replay will be available approximately two hours following the conclusion of the conference call to Friday, November 9, 2012, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 39252322.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
2. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
3. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
4. Valeant Pharmaceuticals To Syndicate Incremental Loans
5. Valeant Pharmaceuticals Announces Management Change
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
8. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
9. Valeant Pharmaceuticals To Host Investor Day
10. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
11. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... March 1, 2017  Numotion, the nation,s leading provider ... of Tek RMD ("robotic mobilization device") by Matia Robotics ... RMD is a motorized standing movement device that offers ... wheelchair to complete everyday activities from a standing position. ... Tek RMD unassisted. Numotion is the exclusive distributor of ...
(Date:3/1/2017)... ... Research and Markets has announced the addition of the "Global ... The Global Infertility Therapy Partnering Terms and Agreements since ... entered into by the world,s leading healthcare companies. The ... are discovery or development stage whereby the licensee obtains a right ...
(Date:3/1/2017)... PRINCETON, N.J. , March 1, ... Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun ... today announced that several new analyses from Phase-1 ... and 2) of tildrakizumab, an investigational IL-23p19 inhibitor ... psoriasis, will be presented at the 2017 Annual ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... ... After a long period of indulging in holidays, many individuals feel ready ... the detox categories, there is a rare yet successful way to cleanse the lungs ... Detox is an herbal-based formula designed to help cleanse people’s lungs from harmful chemicals ...
(Date:3/1/2017)... , ... March 01, 2017 , ... The Industrial Designers ... 5, 2017 by raising awareness of the profession of industrial design (ID) and relaunching ... content geared toward high school students and counselors; parents; and the greater public. , ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... the release of its 2017 update to Compass, the popular online learning ... advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, Compass ...
(Date:3/1/2017)... ... 2017 , ... Grund® America is proud to announce the new ... March 2017 International Housewares Show in Chicago (Grund Booth N6466). , “We are very ... quality,100% OEKO-TEX and GOTS Organic Cotton material. By adding the GOTS (Global Organic ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite ... colorectal cancer screening rates by supporting the 80% by 2018 initiative, led by ... and the National Colorectal Cancer Roundtable (an organization co-founded by ACS and CDC). ...
Breaking Medicine News(10 mins):